Oct 13, 2023
Three stories regarding GLP-1 agonists, imaging during PCI, and the power of sham controls in procedure trials are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. FLOW Trial Positive
Novo Nordisk Stops Ozempic Kidney Trial After Early Signs of Success https://www.medscape.com/s/viewarticle/997237
- FLOW Trial – press release https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166327
II. STEP HFpEF
Semaglutide Win in HFpEF With Obesity Regardless of Ejection Fraction: STEP-HFpEF
https://www.medscape.com/viewarticle/997185
The GLP-1 Agonist Semaglutide in HFpEF Cleared a Low Bar
https://www.medscape.com/viewarticle/995872
- STEP HFpEF substudy
- STEP HFpEF main paper
III. GLP-1 Agonist Adverse Effects
GLP-1 Agonists Linked to Higher Risk for Rare but Serious GI Complications
https://www.medscape.com/viewarticle/997128
- GI Adverse Effects of GLP-1 Agonists https://jamanetwork.com/journals/jama/fullarticle/2810542
IV. Imaging in PCI
Intravascular Imaging in PCI: Time for a Guideline Update?
https://www.medscape.com/viewarticle/995677
- Intravascular imaging during percutaneous coronary intervention: temporal trends and clinical outcomes in the USA https://academic.oup.com/eurheartj/article/44/38/3845/7226277
- HEART Review of Studies of Intracoronary Imaging During PCI https://heart.bmj.com/content/107/9/755
V. The Power of Placebo (Sham) control
Hopeful Insights, No Overall HFpEF Gains From Splanchnic Nerve Ablation: REBALANCE-HF
https://www.medscape.com/viewarticle/997318
- Transvenous Right GSN Ablationin HFpEF https://doi.org/10.1016/j.jchf.2022.05.009
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net